Holen Sie sich die Stockscreener-App
40.80
0.15%
-0.16
Schlusskurs vom Vortag:
$40.96
Offen:
$40.94
24-Stunden-Volumen:
34,632
Relative Volume:
0.07
Marktkapitalisierung:
$1.99B
Einnahmen:
$447.57M
Nettoeinkommen (Verlust:
$-38.92M
KGV:
-49.16
EPS:
-0.83
Netto-Cashflow:
$-1.15M
1W Leistung:
+2.58%
1M Leistung:
+25.08%
6M Leistung:
+101.08%
1J Leistung:
+23.90%
1-Tages-Spanne:
$40.73
$41.14
1-Wochen-Bereich:
$38.90
$41.77
52-Wochen-Spanne:
$18.94
$43.11
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Vergleichen Sie ATRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
40.93 | 1.99B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
587.59 | 209.89B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.35 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
91.20 | 45.33B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
237.24 | 34.84B | 4.93B | 1.25B | 1.38B | 8.47 |
|
WST
West Pharmaceutical Services Inc
|
328.57 | 23.97B | 2.88B | 499.60M | 321.60M | 6.74 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
Transcatheter Aortic Valve Replacement Market Future Business - openPR
AtriCure, Inc. (NASDAQ:ATRC) Shares Purchased by Calamos Advisors LLC - MarketBeat
Atrial Fibrillation Systems Market Witness Booming Demand: - openPR
AtriCure (NASDAQ:ATRC) Stock Price Down 4.9%Should You Sell? - MarketBeat
AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Rating of “Buy” by Brokerages - Defense World
AtriCure (NASDAQ:ATRC) Sets New 1-Year HighHere's What Happened - MarketBeat
Why AtriCure, Inc. (ATRC) Is Skyrocketing Now - MSN
AtriCure (NASDAQ:ATRC) Price Target Raised to $51.00 - Defense World
Trading (ATRC) With Integrated Risk Controls - Stock Traders Daily
AtriCure (NASDAQ:ATRC) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
Needham reiterates Buy on AtriCure shares amid impressive growth and solid valuation - MSN
Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29% - Simply Wall St
AtriCure (NASDAQ:ATRC) Price Target Raised to $51.00 at Needham & Company LLC - MarketBeat
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results - Business Wire
Deep Dive Into AtriCure Stock: Analyst Perspectives (9 Ratings) - Benzinga
Assenagon Asset Management S.A. Has $4.25 Million Holdings in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Assenagon Asset Management S.A. Sells 90,029 Shares of AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
Atrial Fibrillation Surgery Market Trends & Insights 2025 -2033 - openPR
AtriCure stock soars to 52-week high, hits $39.08 - MSN
Orthofix Medical (NASDAQ:OFIX) vs. AtriCure (NASDAQ:ATRC) Head-To-Head Contrast - Defense World
AtriCure (NASDAQ:ATRC) Hits New 52-Week HighShould You Buy? - MarketBeat
AtriCure stock soars to 52-week high, hits $39.08 By Investing.com - Investing.com South Africa
AtriCure reports preliminary results for fourth quarter - MSN
AtriCure (ATRC) Stock Surges Over 5% Amid Market Activity - GuruFocus.com
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by JPMorgan Chase & Co. - MarketBeat
AtriCure projects growth, sets 2025 financial targets By Investing.com - Investing.com Australia
AtriCure projects growth, sets 2025 financial targets - Investing.com
Needham retains AtriCure stock buy rating after revenue beat By Investing.com - Investing.com Australia
AtriCure Q4 revenue prelims beat The Street - Mass Device
Long Term Trading Analysis for (ATRC) - Stock Traders Daily
AtriCure Inc (ATRC) Shares Up 5.13% on Jan 13 - GuruFocus.com
AtriCure (NASDAQ:ATRC) Shares Gap UpShould You Buy? - MarketBeat
AtriCure's (ATRC) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Needham retains AtriCure stock buy rating after revenue beat - Investing.com India
AtriCure (NASDAQ:ATRC) Issues FY 2024 Earnings Guidance - MarketBeat
AtriCure Projects Strong Revenue Growth for 2024 - TipRanks
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day - Business Wire
AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
AtriCure, Inc. (NASDAQ:ATRC) Given Average Rating of “Buy” by Analysts - Defense World
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):